Page 39 - Priority Review News Today

(2023-09-29 | NDAQ:HCM) HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Odronextamab is under Priority Review for the treatment of adults with R/R FL or R/R DLBCL who have progressed after ≥2 prior systemic therapies.

The FDA has accepted for Priority Review the BLA for sotatercept for the treatment of adults with pulmonary arterial hypertension (WHO Group 1).

The FDA has accepted for Priority Review the NDA for intranasally administered scopolamine gel as a preventive therapy for motion sickness.

After a volatile end to the summer, can investors look forward to a gentler autumn? There is some reason to hope so, according to Sharmin Mossavar-Rahmani, chief investment officer of wealth management at Goldman Sachs. This year, as the S&P 500 rebounded from the 19% loss it sustained in 2022, Mossavar-Rahmani has seen her bullish position vindicated, and she believes recent earnings trends and the receding probability of a recession promise further gains to come. In an interview with Barr...

Sanofi (SNY) announced the FDA has accepted for Priority Review the supplemental Biologics License Application for Dupixent to treat children aged 1 to 11 years with eosinophilic esophagitis.

(RTTNews) - French stocks declined on Tuesday, the dollar reached its peak for the year and the 10-year U.S. Treasury yield topped 4.5 percent ami...

  Dupixent® sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and only treatment indicated in...

26.09.2023 - CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its ... Seite 1

/PRNewswire/ -- The "Pharmaceutical Regulatory Affairs Market Size, Share & Trends Analysis Report By Services, By Category, By Service Provider, By Company...